This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n5http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n7http://linked.opendata.cz/resource/fda-spl/ingredient/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/mesh/
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n8http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C1379
rdf:type
owl:Class
rdfs:label
Fulvestrant
rdfs:subClassOf
nci:C1821
nci:A8
nci:C63923
nci:P106
Pharmacologic Substance Organic Chemical
nci:P108
Fulvestrant
nci:P175
719276
nci:P207
C0935916
nci:P210
129453-61-8
nci:P302
Hormone receptor-positive metastatic breast cancer
nci:P303
Breast cancer; Endometrial cancer; Prostate cancer
nci:P319
22X328QOC4
nci:P322
FDA
nci:P325
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A drug used to treat certain types of breast cancer in postmenopausal women. It is also being studied in the treatment of other types of cancer. Faslodex blocks estrogen activity in the body and is a type of antiestrogen.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
nci:P329
43053
nci:P330
43053
nci:P350
C32H47F5O3S
nci:P366
Fulvestrant
nci:P368
CHEBI:31638
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Faslodex</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>fulvestrant</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000306498</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ZD9238</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Fulvestrant</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>DCP</n0:term-source><n0:source-code>20048</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>FULVESTRANT</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>22X328QOC4</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Faslodex</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000415316</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Faslodex(ICI 182,780)</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0719276</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Fulvestrant</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ICI 182780</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000045005</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ICI 182,780</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C1379
owl:sameAs
n7:22X328QOC4 n8:N0000010122
n4:hasConcept
n5:M0397101